ArticleCureus2025
Role of Echocardiography in Detecting Left Ventricular Dysfunction Among Diabetic Patients: A Clinical and Biochemical Perspective.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes mellitus (DM) increases the risk of left ventricular dysfunction (LVD), which can progress to heart failure if undetected. Echocardiography, a non-invasive and cost-effective imaging tool, provides real-time assessment of left ventricular (LV) function and enables early detection of myocardial dysfunction using advanced techniques such as tissue Doppler imaging and strain analysis. Diabetic patients are particularly prone to LVD due to chronic hyperglycemia, insulin resistance, and systemic inflammation, leading to myocardial fibrosis, microvascular dysfunction, and oxidative stress. This study evaluates the role of echocardiography in detecting subclinical and overt LVD in diabetic patients and explores associated clinical and biochemical risk factors.
methodsThis observational cohort study included 500 diabetic patients aged 30-70 years, with the sample size determined using power calculation (95% confidence level, 5% margin of error). Stratified random sampling was used for participant selection, with hospital-based recruitment noted as a limitation. Patients underwent clinical evaluation, biochemical analysis, and echocardiographic assessment, including left ventricular ejection fraction (LVEF), diastolic function indicators, and LV mass index. Biochemical markers analyzed included fasting blood glucose, HbA1c, lipid profile, and high-sensitivity C-reactive protein (hs-CRP), which was selected for its strong association with cardiovascular risk and myocardial dysfunction. Data analysis was performed using IBM SPSS Statistics for Windows, Version 26 (Released 2019; IBM Corp., Armonk, New York, United States), applying descriptive statistics, correlation studies, and multivariate logistic regression, with adjustments for age, gender, BMI, hypertension, and diabetes duration.
resultsAmong the 500 participants, 140 (28%) exhibited diastolic dysfunction, while 90 (18%) had reduced LVEF (<50%), indicating diastolic dysfunction as the predominant abnormality. Patients with LVD had worse glycemic control and higher systemic inflammation markers than those with normal LV function. hs-CRP negatively correlated with the LVEF (r = -0.34, p = 0.022) and positively with the LV mass index (r = 0.38, p < 0.05), highlighting its role in myocardial remodeling. Multivariate analysis identified poor glycemic control and systemic inflammation as key predictors of LVD. Subgroup analysis showed that older patients (≥60 years) and those with diabetes duration >10 years had a higher prevalence of diastolic dysfunction and an increased LV mass index, suggesting progressive myocardial remodeling over time.
conclusionEchocardiography is a critical tool for early LVD detection, even in asymptomatic diabetic patients. Findings emphasize routine echocardiographic screening, particularly in those with diabetes duration ≥10 years, poor glycemic control (HbA1c >7%), or elevated hs-CRP levels, recommending assessments at least annually or sooner if symptoms arise. Managing glycemic and lipid profiles, alongside targeted inflammation-reducing strategies, such as anti-inflammatory pharmacologic interventions (e.g., statins, SGLT2 inhibitors, IL-6 inhibitors) and lifestyle modifications (diet, exercise, weight management), is essential for lowering cardiovascular risk. Integrating echocardiographic evaluation into routine diabetic care can help reduce the burden of diabetic cardiomyopathy and improve long-term cardiovascular outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.